Compare CYTK & OGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYTK | OGE |
|---|---|---|
| Founded | 1997 | 1902 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 10.2B |
| IPO Year | 2004 | 2009 |
| Metric | CYTK | OGE |
|---|---|---|
| Price | $75.87 | $47.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 9 |
| Target Price | ★ $89.26 | $48.78 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.59% |
| EPS Growth | N/A | ★ 5.94 |
| EPS | N/A | ★ 0.24 |
| Revenue | $13,368,000.00 | ★ $3,260,100,000.00 |
| Revenue This Year | $7.37 | $3.74 |
| Revenue Next Year | $310.19 | $1.42 |
| P/E Ratio | ★ N/A | $197.92 |
| Revenue Growth | N/A | ★ 9.21 |
| 52 Week Low | $35.22 | $41.70 |
| 52 Week High | $88.31 | $50.59 |
| Indicator | CYTK | OGE |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 45.31 |
| Support Level | $73.95 | $46.21 |
| Resistance Level | $80.65 | $49.14 |
| Average True Range (ATR) | 2.94 | 0.88 |
| MACD | -0.58 | -0.03 |
| Stochastic Oscillator | 26.45 | 32.12 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
OGE Energy is a holding company for Oklahoma Gas & Electric, a regulated utility with electricity generation, transmission, and distribution service for 900,000 customers in Oklahoma and western Arkansas. In December 2021, OGE divested its 25.5% stake in Enable Midstream Partners, an oil and gas services company it created in 2013 through a unit exchange merger with Energy Transfer. OGE sold its 95.4 million limited partner units of Energy Transfer throughout 2022. OGE sold its retail gas business in 1928 and no longer has any gas operations.